A5102973789- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Tracheal and airway disorders
- Cancer Research and Treatments
- Appendicitis Diagnosis and Management
- Tryptophan and brain disorders
- Head and Neck Surgical Oncology
- Estrogen and related hormone effects
- Intraperitoneal and Appendiceal Malignancies
- Circular RNAs in diseases
- Genetic Associations and Epidemiology
- Chemokine receptors and signaling
- Acute Kidney Injury Research
Hospital Universitario de Valme
2020-2024
Hospital Universitario Virgen del Rocío
2007-2021
Instituto de Biomedicina de Sevilla
2016-2021
Universidad de Sevilla
2016-2021
Instituto de Salud Carlos III
2021
Centro de Investigación Biomédica en Red de Cáncer
2021
Consejo Superior de Investigaciones Científicas
2021
Marqués de Valdecilla University Hospital
2007
Hospital Clínico San Carlos
2006
Hospital Universitari Sant Joan D'Alacant
2005
The aim of this phase III trial was to compare the efficacy and safety capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC).A total 348 patients were randomly assigned receive XELOX (oral 1,000 mg/m2 bid 14 days 130 on day 1 every 3 weeks) or FUOX (continuous-infusion FU 2,250 during 48 hours 1, 8, 15, 22, 29, 36 85 29 6 weeks).There no significant differences...
MicroRNAs (miRNAs) are involved in numerous biological and pathological processes including colorectal cancer (CRC). The aim of our study was to evaluate the ability miRNA expression patterns predict chemotherapy response a cohort 78 patients with metastatic CRC (mCRC). We examined levels 667 miRNAs training evaluated their potential association relevant clinical endpoints. identified profile that analysed by RT-qPCR an independent cohort. For set selected miRNAs, bioinformatic target...
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) are a heterogeneous group of malignant that can settle in the gastroenteropancreatic tract. They composed (NE) and non-NE component at least 30% each tumour. The include different histological combinations glandular, squamous, mucinous sarcomatoid phenotypes, one or both components be low-or high grade malignant. Recent changes nomenclature these might lead to great deal confusion, lack specific clinical trials is main reason why...
Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC.To assess whether therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) patients with HNSCC.This multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 from November 2, 2011, to July 4,...
Abstract Background Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits compared single-agent immunotherapy. Epacadostat, an indoleamine 2,3 dioxygenase 1 inhibitor, plus pembrolizumab, PD-1 showed promising activity in advanced HNSCC the phase 1/2 KEYNOTE-037/ECHO-202 trial. Methods KEYNOTE-669/ECHO-304 is randomized, open-label, 3 study...
// María-José de Miguel-Luken 1 , Manuel Chaves-Conde Verónica 2 Sandra Muñoz-Galván 3 José Luis López-Guerra 4 Juan C. Mateos Jerónimo Pachón David Chinchón 5 Vladimir Suarez and Amancio Carnero Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain University Málaga, Instituto Biomedicina Sevilla, IBIS, Universidad Consejo Superior Investigaciones Científicas, Radiation Pathology, Correspondence to: Carnero, email: Keywords : MAP17, ROS, SGLT, biomarker,...
Background Non-hereditary colorectal cancer (CRC) is a complex disorder resulting from the combination of genetic and non-genetic factors. Genome–wide association studies (GWAS) are useful for identifying such susceptibility However, single loci so far associated with CRC only represent fraction risk development in general population. Therefore, many other variants alone must still remain to be discovered. The aim this work was search factors CRC, by performing single-locus two-locus GWAS...
Current larynx preservation treatments have achieved an improvement of laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities and recurrences. At present, there is no evidence select the group patients that may benefit from approaches instead surgery. Therefore, laryngeal biomarkers could facilitate pretreatment identification who respond chemoradiation-based therapy. In this study, we evaluated retrospectively 53 with cancer determine whether gH2AX...
The optimal sequence of chemotherapeutic agents is not firmly established for the treatment metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated efficacy and tolerability a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients mCRC. Patients received intravenous 175 mg/m2 on day 1 oral 1000 (800 >65 years age) twice daily days 2–8, followed by 1-week rest, 5 mg/kg as an infusion every 2 weeks. Seventy-seven were...
6001 Background: Locally advanced HNSCC is treated curatively, but recurrence common. In HNSCC, EGFR richly expressed and inhibition validated treatment (tx); the ErbB family blocker afatinib (A) showed efficacy in recurrent/metastatic disease. This Phase III trial assessed if A after definitive CRT improves disease-free survival (DFS). Methods: Eligible pts had complete response ≥66 Gy (or equivalent) with concurrent cisplatin or carboplatin not prior inhibition, for of oral cavity,...
3524 Background: Ox plus CI 5-FU is one of the standard chemotherapy regimens for first-line treatment in patients (p) with advanced CRC. Phase II trials have shown CapeOx as a convenient combination, high activity and favourable safety profile. This study phase III trial comparing both schedules. Methods: The designed to include 348 p histological or cytological confirmation advanced/metastatic CRC adenocarcinoma, measurable disease, PS≥70% adequate bone marrow, renal hepatic function....
3580 Background: OX plus CI 5-FU is one of the standard chemotherapy regimens for first-line treatment in patients (p) with advanced CRC. Phase II trials have shown XELOX as a convenient combination, high activity and favourable safety profile. This study phase III trial comparing both schedules. Methods: Multicenter, randomized open labeled was designed to include p withadvanced/metastatic CRC adenocarcinoma, measurable disease, PS ≥70% adequate bone marrow, renal hepatic functions....
Lenvatinib is an oral multityrosine kinase inhibitor (TKI) with proven effectiveness in the treatment of radioactive iodine- (RAI-) refractory and/or unresectable differentiated thyroid carcinoma (DTC). The present study reports case a 41-year-old male who underwent hemithyroidectomy June 2015 due to nodule fine-needle aspiration follicular neoplasm cytology and no evidence malignancy histopathological exam. Three years later, acute disabling clinical symptoms emerged, mainly high skeletal...
e14025 Background: Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has shown efficacy and is well tolerated in combination with chemotherapy (CT) for the treatment of mCRC. The main objective this study was to evaluate safety panitumumab plus irinotecan as second-line irinotecan-naïve mCRC patients (pts). K-RAS status negative predictive marker not established by time trial planned started. A protocol amendment performed recruit only wild-type...